The Drugs Controller General of India (DCGI) has called for the timely reporting of adverse events related to medical devices by issuing a circular dated May 15, 2024. The move aims to strengthen the existing Materiovigilance Programme of India (MvPI) ensuring that medical devices are safe and reliable once in the market.
The Materiovigilance Programme of India (MvPI) is an important programme for reporting adverse events, coordinated analysis related to medical devices, including in-vitro diagnostic devices, therefore it is suggested that all the license holders should also use the MvPI platform to report any adverse events/serious adverse events associated with the devices to enhance the procedure of identifying risk associated with medical devices.
The Materiovigilance Programme of India (MvPI) was launched by the Ministry of Health and Family Welfare, Government of India, on July 6, 2015, with the objective to monitor, record and analyse the root cause of adverse events or risks associated with the use of medical devices, including in-vitro diagnostics by healthcare professionals or patients/users and suggesting regulatory bodies to take appropriate action to improve Indian patients’ safety. Indian Pharmacopeia Commission (IPC) is functioning as National Coordination Center (NCC) for MvPI.
The core objectives of MvPI are as follows:
Medical device organisations, including in-vitro diagnostics, are important stakeholders to make the MvPI programme a success. The key responsibilities of such organisations as a result of the MvPI are as follows:
MvPI is a critical components of India's healthcare delivery system, guaranteeing the safety and efficacy of medical devices while increasing healthcare quality. Prioritizing transparency and employing cutting edge technology can create an efficient Materiovigilance system which can protect public health while improving healthcare quality.
For more information on India's Materiovigilance Programme and its effect on medical device safety, visit, https://www.ipc.gov.in/mandates/materiovigilance-programme-of-india-mvpi/about-us.html.
Regulatory Solutions India (RSI) is your reliable partner when it comes to medical device regulation. Since 2011, they have successfully registered over 450 products ranging from medical devices, IVDs and cosmetics across 25+ categories such as stents, catheters, intraocular lenses, orthopedic implants, ablation devices surgical dressings, hypodermic syringes/needles and more from clients from 15+ countries.
RSI provides its clients with a unique combination of technical, strategic and project management support backed by rich industry experience. We help companies register their products with India's central licensing authority (CDSCO) while offering expert knowledge into CDSCO medical device registration and import license processes in order to navigate successfully the regulatory landscape.
Partner with Regulatory Solutions India to ensure the safety and security of the medical devices. Visit us here.